Topline results from the STEP Young trial show once-weekly injectable semaglutide (Wegovy) produced greater BMI reductions than placebo in children aged 6 to 11 with obesity. Of children receiving semaglutide, 40.4% were no longer classified as having obesity after 68 weeks, while all placebo participants still met obesity criteria. Safety and tolerability were consistent with prior semaglutide studies.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.